Literature DB >> 33309741

The deubiquitinase CYLD controls protective immunity against helminth infection by regulation of Treg cell plasticity.

Jee H Lee1, Le Zou2, Runqing Yang3, Jihye Han4, Qingqing Wan2, Xian Zhang3, Sarah El Baghdady4, Andrea Roman4, Chris Elly4, Hyung-Seung Jin5, Yoon Park6, Michael Croft7, Yun-Cai Liu8.   

Abstract

BACKGROUND: Type 2 immunity can be modulated by regulatory T (Treg) cell activity. It has been suggested that the deubiquitinase cylindromatosis (CYLD) plays a role in the development or function of Treg cells, implying that it could be important for normal protective immunity, where type 2 responses are prevalent.
OBJECTIVE: We sought to investigate the role of CYLD in Treg cell function and TH2 cell immune responses under steady-state conditions and during helminth infection.
METHODS: Foxp3-restricted CYLD conditional knockout (KO) mice were examined in mouse models of allergen-induced airway inflammation and Nippostrongylus brasiliensis infection. We performed multiplex magnetic bead assays, flow cytometry, and quantitative PCR to understand how a lack of CYLD affected cytokine production, homing, and suppression in Treg cells. Target genes regulated by CYLD were identified and validated by microarray analysis, coimmunoprecipitation, short hairpin RNA knockdown, and transfection assays.
RESULTS: Treg cell-specific CYLD KO mice showed severe spontaneous pulmonary inflammation with increased migration of Treg cells into the lung. CYLD-deficient Treg cells furthermore produced high levels of IL-4 and failed to suppress allergen-induced lung inflammation. Supporting this, the conditional KO mice displayed enhanced protection against N brasiliensis infection by contributing to type 2 immunity. Treg cell conversion into IL-4-producing cells was due to augmented mitogen-activated protein kinase and nuclear factor κB signaling. Moreover, Scinderin, a member of the actin-binding gelsolin family, was highly upregulated in CYLD-deficient Treg cells, and controlled IL-4 production through forming complexes with mitogen-activated protein kinase kinase/extracellular receptor kinase. Correspondingly, both excessive IL-4 production in vivo and the protective role of CYLD-deficient Treg cells against N brasiliensis were reversed by Scinderin ablation.
CONCLUSIONS: Our findings indicate that CYLD controls type 2 immune responses by regulating Treg cell conversion into TH2 cell-like effector cells, which potentiates parasite resistance.
Copyright © 2020 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CYLD deubiquitinase; Helminth infection; MAPK signaling; NF-κB signaling; Scinderin; Treg cells; lung inflammation; type 2 immunity

Mesh:

Substances:

Year:  2020        PMID: 33309741      PMCID: PMC8729234          DOI: 10.1016/j.jaci.2020.10.042

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   14.290


  63 in total

1.  Differential response of regulatory and conventional CD4⁺ lymphocytes to CD3 engagement: clues to a possible mechanism of anti-CD3 action?

Authors:  Li Li; Junko Nishio; André van Maurik; Diane Mathis; Christophe Benoist
Journal:  J Immunol       Date:  2013-08-28       Impact factor: 5.422

Review 2.  Regulation generation: the suppressive functions of human regulatory T cells.

Authors:  Wendy A Goodman; Kevin D Cooper; Thomas S McCormick
Journal:  Crit Rev Immunol       Date:  2012       Impact factor: 2.214

3.  Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces.

Authors:  Yuri P Rubtsov; Jeffrey P Rasmussen; Emil Y Chi; Jason Fontenot; Luca Castelli; Xin Ye; Piper Treuting; Lisa Siewe; Axel Roers; William R Henderson; Werner Muller; Alexander Y Rudensky
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

4.  Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis.

Authors:  Fabian Flores-Borja; Elizabeth C Jury; Claudia Mauri; Michael R Ehrenstein
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-26       Impact factor: 11.205

Review 5.  Mechanisms of foxp3+ T regulatory cell-mediated suppression.

Authors:  Ethan M Shevach
Journal:  Immunity       Date:  2009-05       Impact factor: 31.745

6.  New asthma biomarkers: lessons from murine models of acute and chronic asthma.

Authors:  Emmanuel Di Valentin; Céline Crahay; Nancy Garbacki; Benoit Hennuy; Maud Guéders; Agnès Noël; Jean-Michel Foidart; Johan Grooten; Alain Colige; Jacques Piette; Didier Cataldo
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-11-21       Impact factor: 5.464

7.  Preexisting helminth infection induces inhibition of innate pulmonary anti-tuberculosis defense by engaging the IL-4 receptor pathway.

Authors:  Julius A Potian; Wasiulla Rafi; Kamlesh Bhatt; Amanda McBride; William C Gause; Padmini Salgame
Journal:  J Exp Med       Date:  2011-08-08       Impact factor: 14.307

8.  Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo.

Authors:  Xuyu Zhou; Samantha L Bailey-Bucktrout; Lukas T Jeker; Cristina Penaranda; Marc Martínez-Llordella; Meredith Ashby; Maki Nakayama; Wendy Rosenthal; Jeffrey A Bluestone
Journal:  Nat Immunol       Date:  2009-07-26       Impact factor: 25.606

9.  MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion.

Authors:  Christopher J Oliphant; You Yi Hwang; Jennifer A Walker; Maryam Salimi; See Heng Wong; James M Brewer; Alexandros Englezakis; Jillian L Barlow; Emily Hams; Seth T Scanlon; Graham S Ogg; Padraic G Fallon; Andrew N J McKenzie
Journal:  Immunity       Date:  2014-07-31       Impact factor: 31.745

10.  Tissue-Restricted Adaptive Type 2 Immunity Is Orchestrated by Expression of the Costimulatory Molecule OX40L on Group 2 Innate Lymphoid Cells.

Authors:  Timotheus Y F Halim; Batika M J Rana; Jennifer A Walker; Bernhard Kerscher; Martin D Knolle; Helen E Jolin; Eva M Serrao; Liora Haim-Vilmovsky; Sarah A Teichmann; Hans-Reimer Rodewald; Marina Botto; Timothy J Vyse; Padraic G Fallon; Zhi Li; David R Withers; Andrew N J McKenzie
Journal:  Immunity       Date:  2018-06-12       Impact factor: 43.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.